ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07

Its studies are mostly in Lymphoma, led by 2 companies.

Furthest: phase 2, since Oct 27, 20222 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EpimAb Biotherapeutics (Suzhou)its history only11 open or runningphase 1since Oct 27, 2022Oct 27, 2022none ahead
Shanghai EpimAb Biotherapeuticsits history only11 open or runningphase 2since Feb 6, 2026Feb 6, 2026Jun 30, 2028phase 2 · NCT07432022

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2022First study: phase 1 study in RecurrenceNew to EpimAb Biotherapeutics (Suzhou)EpimAb Biotherapeutics (Suzhou) · NCT05607498 · 150 planned · Australia, China
  2. Feb 6, 2026Shanghai EpimAb Biotherapeutics’ first study: phase 2 study in Combination TherapyNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT07432022 · 115 planned · China

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Combination TherapyShanghai EpimAb Biotherapeutics · NCT07432022

TargetBeta

CD3E →ROR1 →read by rule
“A bispecific antibody directed against both the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07432022Combination Therapy · China2RecruitingShanghai EpimAb BiotherapeuticsJun 30, 2028115
NCT05607498Recurrence · Australia, China1RecruitingEpimAb Biotherapeutics (Suzhou)Oct 31, 2025150

How it is read

Names in the registry

  • “EMB07”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.